Efecte de l'administració de l'rt-PA en condicions isquèmiques in vitro i in vivo: Cav-1 com a potencial biomarcador de volum d'infart 

Comajoan von Arend, Pau (Date of defense: 2019-12-18)

Recombinant tissue plasminogen activator (rt-PA) is currently the only FDA-approved drug for the treatment of acute ischaemic stroke. However, the application of this therapy is limited to <5-7% of patients due to the ...